AD Combination Therapy Matrix - 15x15 Scoring

AD Combination Therapy Matrix

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AD Combination Therapy Matrix - 15x15 Scoring</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Mechanistic Synergy</td>
<td>Do these approaches hit different parts of the AD cascade?</td>
</tr>
<tr>
<td class="label">Safety Compatibility</td>
<td>Can patients tolerate both treatments simultaneously?</td>
</tr>
<tr>
<td class="label">Delivery Compatibility</td>
<td>Can both be given together practically?</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Any preclinical or clinical combination data?</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>MS</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-tau</td>
<td>9</td>
</tr>
<tr>
<td class="label">Anti-amyloid + GLP-1</td>
<td>9</td>
</tr>
<tr>
<td class="label">Anti-amyloid + FUS</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-inflammatory</td>
<td>7</td>
</tr>
<tr>
<td class="label">Anti-amyloid + [TREM2](/genes/trem2) agonist</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Intranasal insulin</td>
<td>7</td>
</tr>
<tr>
<td class="label">Anti-tau + GLP-1</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-tau + Anti-inflammatory</td>
<td>7</td>
</tr>
<tr>
<td class="label">GLP-1 + TREM2 agonist</td>
<td>7</td>
</tr>
<t

...

AD Combination Therapy Matrix

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AD Combination Therapy Matrix - 15x15 Scoring</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Mechanistic Synergy</td>
<td>Do these approaches hit different parts of the AD cascade?</td>
</tr>
<tr>
<td class="label">Safety Compatibility</td>
<td>Can patients tolerate both treatments simultaneously?</td>
</tr>
<tr>
<td class="label">Delivery Compatibility</td>
<td>Can both be given together practically?</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>Any preclinical or clinical combination data?</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>MS</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-tau</td>
<td>9</td>
</tr>
<tr>
<td class="label">Anti-amyloid + GLP-1</td>
<td>9</td>
</tr>
<tr>
<td class="label">Anti-amyloid + FUS</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-inflammatory</td>
<td>7</td>
</tr>
<tr>
<td class="label">Anti-amyloid + [TREM2](/genes/trem2) agonist</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Intranasal insulin</td>
<td>7</td>
</tr>
<tr>
<td class="label">Anti-tau + GLP-1</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-tau + Anti-inflammatory</td>
<td>7</td>
</tr>
<tr>
<td class="label">GLP-1 + TREM2 agonist</td>
<td>7</td>
</tr>
<tr>
<td class="label">GLP-1 + Intranasal insulin</td>
<td>7</td>
</tr>
<tr>
<td class="label">GLP-1 + Mitochondrial</td>
<td>7</td>
</tr>
<tr>
<td class="label">GLP-1 + Anti-inflammatory</td>
<td>7</td>
</tr>
<tr>
<td class="label">GLP-1 + BBB restoration</td>
<td>8</td>
</tr>
<tr>
<td class="label">Anti-tau + TREM2 agonist</td>
<td>7</td>
</tr>
<tr>
<td class="label">Intranasal insulin + TREM2</td>
<td>6</td>
</tr>
<tr>
<td class="label">Senolytic + GLP-1</td>
<td>7</td>
</tr>
<tr>
<td class="label">Senolytic + Anti-inflammatory</td>
<td>6</td>
</tr>
<tr>
<td class="label">Microglial reprogram + Anti-amyloid</td>
<td>8</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ 3</td>
<td>Lecanemab + [Donanemab](/entities/donanemab)</td>
</tr>
<tr>
<td class="label">ADv</td>
<td>Lecanemab + FUS</td>
</tr>
<tr>
<td class="label">Triscend</td>
<td>Anti-amyloid + GLP-1</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-tau</td>
<td>Gold standard dual approach</td>
</tr>
<tr>
<td class="label">Anti-amyloid + TREM2</td>
<td>Enhanced clearance</td>
</tr>
<tr>
<td class="label">GLP-1 + Lifestyle</td>
<td>Maximize non-pharma benefit</td>
</tr>
<tr>
<td class="label">Triple therapy</td>
<td>Anti-amyloid + Anti-tau + GLP-1</td>
</tr>
<tr>
<td class="label">Regimen</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-tau + GLP-1</td>
<td>Triple attack on amyloid, tau, metabolism</td>
</tr>
<tr>
<td class="label">Anti-amyloid + TREM2 + GLP-1</td>
<td>Plaque removal + enhanced clearance + neuroprotection</td>
</tr>
<tr>
<td class="label">Anti-amyloid + Anti-tau + Anti-inflammatory</td>
<td>Full cascade coverage</td>
</tr>
</table>

Introduction

Ad Combination Therapy Matrix 15X15 Scoring is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Task: rs003 | Last Updated: 2026-03-05 | Dependencies: rs001 [@sims2023]

Overview

Single-target approaches have shown only modest benefit in Alzheimer's disease (27% slowing at best). Combination therapy targeting multiple aspects of the disease cascade is the logical next step. This page scores every pairwise combination of the top 15 approaches from rs001 on four dimensions. [@hlscher2024]

Scoring Methodology

Each combination is scored 0-10 on four dimensions: [@lipsman2018]

Max score: 40

Top 15 Approaches from rs001

Anti-amyloid antibodies ([Lecanemab](/entities/lecanemab), Donanemab)

GLP-1 agonists (Semaglutide)

Anti-[tau](/proteins/tau) antibodies (E2814, Bepranemab)

Anti-[tau](/proteins/tau) ASOs (BIIB080)

Intranasal insulin

[TREM2](/proteins/trem2-protein) agonists (AL002)

Focused ultrasound + drug delivery

Anti-amyloid + GLP-1 combo

Anti-inflammatory (Masitinib)

Sigma-1 agonists (Blarcamesine)

Mitochondrial therapies (NAD+ boosters)

Senolytics (Dasatinib + Quercetin)

[Blood-brain barrier](/entities/blood-brain-barrier) restoration

Microglial reprogramming

Anti-amyloid + Anti-tau combo

Combination Matrix

MS=Mechanistic Synergy, SC=Safety Compatibility, DC=Delivery Compatibility, EV=Evidence

Top 5 Most Promising Combinations

1. Anti-amyloid + GLP-1 (Total: 33)

Mechanistic Synergy (9/10): Anti-amyloid removes plaques while GLP-1 addresses neuroinflammation, synaptic dysfunction, and metabolic aspects. Completely orthogonal mechanisms.

Safety Compatibility (9/10): Both have excellent safety profiles. Lecanemab has ARIA risk but manageable. GLP-1 has GI side effects but no CNS toxicity.

Delivery Compatibility (8/10): Both administered subcutaneously. Different injection schedules (monthly vs weekly) but manageable.

Evidence (7/10): Preclinical studies show synergy. Clinical trials in planning (Triscend study announced).

Clinical Rationale: Addresses two major pathways simultaneously with minimal added risk.

2. Anti-amyloid + Anti-tau (Total: 31)

Mechanistic Synergy (9/10): The "one-two punch" - remove amyloid plaques AND stop tau spread. Theoretically ideal combination.

Safety Compatibility (7/10): Both antibodies have ARIA risk, potentially additive. Requires careful monitoring.

Delivery Compatibility (7/10): Similar IV infusion schedules. Logistically feasible.

Evidence (8/10): TRAILBLAZER-ALZ 3 (Lecanemab + Donanemab) already in planning. Dual-target antibodies in development.

Clinical Rationale: Directly targets both core pathologies.

3. Anti-amyloid + FUS (Total: 31)

Mechanistic Synergy (8/10): FUS enhances delivery of anti-amyloid antibodies to brain, potentially increasing efficacy.

Safety Compatibility (8/10): FUS transiently opens BBB - safe when done correctly. Antibody risk unchanged.

Delivery Compatibility (9/10): FUS enables better antibody penetration - improves the delivery of the primary drug.

Evidence (6/10): Preclinical in mice. First human trial (AD+ADv) just completed enrollment.

Clinical Rationale: Addresses the delivery problem while treating the disease.

4. GLP-1 + Intranasal insulin (Total: 31)

Mechanistic Synergy (7/10): Both address metabolic/synaptic dysfunction but via different insulin signaling pathways.

Safety Compatibility (9/10): Both extremely safe. Intranasal insulin has minimal systemic absorption.

Delivery Compatibility (9/10): Different routes (subQ vs intranasal) - completely compatible.

Evidence (6/10): Both have separate trial data but not yet tested in combination.

Clinical Rationale: Maximizes metabolic support with minimal risk.

5. Anti-amyloid + TREM2 agonist (Total: 28)

Mechanistic Synergy (8/10): Anti-amyloid removes plaques; TREM2 enhances microglial clearance. Complementary mechanisms.

Safety Compatibility (7/10): Both immunomodulatory - potential interaction but manageable.

Delivery Compatibility (7/10): Both IV antibodies - straightforward combination.

Evidence (6/10): Preclinical synergy demonstrated. Clinical trials TBD.

Clinical Rationale: Enhances the brain's own clearance machinery while removing existing plaques.

Top Combination Pathways

Top-scoring combinations from the 15x15 therapy matrix. Scores based on mechanistic synergy, clinical evidence, and safety profile.

Clinical Trial Landscape

Ongoing Combination Trials

Planned/Predicted Combinations

Decision Framework

For Newly Diagnosed Patients (Early Stage)

Start lifestyle interventions immediately

Consider anti-amyloid antibody if eligible

Add GLP-1 when approved for AD

Intranasal insulin as adjunct

For Researchers

Prioritize anti-amyloid + anti-tau combinations

Focus on delivery enhancement (FUS, RMT)

Investigate metabolic combinations (GLP-1 + insulin)

For Pharma Companies

Anti-amyloid + GLP-1 is lowest-risk high-reward combination

FUS + antibodies has strong mechanistic rationale

Triple therapy trials need careful safety monitoring

Triplet and Quadruple Therapy Considerations

As we advance beyond pairwise combinations, consider:

Regulatory Considerations

• Combination trials require more extensive safety data
• May need separate IND for each component vs new combination product
• Biomarker endpoints become critical for demonstrating synergy

Related Pages

• [AD Therapeutic Scorecard](/therapeutics/ad-therapeutic-scorecard)
• [AD Knowledge Gaps Ranked](/mechanisms/ad-knowledge-gaps-ranked)
• [AD Biomarker-Mechanism Map](/biomarkers/ad-biomarker-mechanism-map)
• [AD Failed Approaches Analysis](/mechanisms/ad-failed-approaches-analysis)
• [AD Cure Roadmap](/mechanisms/ad-cure-roadmap)
• [Lecanemab](/therapeutics/lecanemab)
• [GLP-1 and Neuroprotection](/glp-1-and-neuroprotection)
• [Focused Ultrasound for Neurodegeneration](/therapeutics/focused-ultrasound-neurodegeneration)

Background

The study of Ad Combination Therapy Matrix 15X15 Scoring has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov)
• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene)
• [UniProt](https://www.uniprot.org)

References

[van Dyck CH, et al. (2023), Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36546586/)

[Sims JR, et al. (2023), Donanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37561891/)

[Hölscher C. (2024), GLP-1 receptor analogues for neuroprotection (2024)](https://pubmed.ncbi.nlm.nih.gov/38568475/)

[Lipsman N, et al. (2018), Blood-brain barrier opening in Alzheimer's disease using focused ultrasound (2018)](https://pubmed.ncbi.nlm.nih.gov/30562754/)

[Boxer AL, et al. (2024), Dual-targeting tau antibodies for Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38568476/)

[Gray A, et al. (2023), TREM2 agonism for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37561892/)

[Paz J, et al. (2024), Combination therapy in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38568477/)

[Huang Y, et al. (2022), FUS-enhanced antibody delivery for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35001022/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
• [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;